FDA Grants Breakthrough Therapy Designation to Glycomine's GLM101 for PMM2-CDG

Glycomine announced that the FDA has granted Breakthrough Therapy designation to GLM101 for the treatment of phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG), a serious, multisystem disorder with no approved treatments.¹ FDA grants Breakthrough Therapy designation to investigational drugs for serious conditions when preliminary clinical evidence indicates the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint; the designation is intended to support more efficient development and review through closer engagement with FDA.¹

What is GLM101 and how does it work?

GLM101 is an investigational liposomal mannose-1-phosphate substrate replacement therapy designed to address the underlying mannose-1-phosphate deficiency and resulting disruption of glycosylation in PMM2-CDG.¹ The therapy has already received Orphan Drug Designation in the US and EU, as well as Rare Pediatric Disease and Fast Track designations in the US.¹

What clinical evidence supported the designation?

The Breakthrough Therapy designation is based on clinical evidence from Glycomine's open-label Phase 2a study, including improvements in ataxia and other clinical measures after 24 weeks of GLM101 treatment.¹

"This designation reflects the compelling clinical evidence generated to date and the urgent need for a treatment for people living with PMM2-CDG," said Steven Axon, chief executive officer, Glycomine. "It also gives us the opportunity for more frequent discussions with FDA as we analyze the POLAR data and determine the next steps for GLM101."¹

GLM101 is currently being evaluated in POLAR, a global, randomized, double-blind, placebo-controlled Phase 2b study that enrolled 43 pediatric and adult patients with PMM2-CDG across 15 sites in the US, UK, and Europe.¹ Topline data from the randomized portion of POLAR are expected in the fourth quarter of 2026, after which all patients may receive GLM101 through Week 48, generating additional data on longer-term safety, durability of response, and outcomes for patients who cross over from placebo.¹

What is PMM2-CDG?

PMM2-CDG, previously known as CDG-Ia, is the most prevalent congenital disorder of glycosylation, caused by genetic mutations in phosphomannomutase 2 (PMM2), an enzyme that converts mannose-6-phosphate to mannose-1-phosphate.¹ Mannose-1-phosphate is required to build the N-glycans essential for proper protein structure and function; its deficiency disrupts N-glycosylation broadly and can produce a wide array of clinical symptoms that are, in many cases, life-threatening.¹ Glycomine's release estimates a birth incidence of 1 in 30,000 to 1 in 40,000 in Europe and the United States.¹ A peer-reviewed review of PMM2-CDG's endocrine manifestations notes the disorder affects more than 1,000 diagnosed patients worldwide and frequently involves endocrine dysfunction, including hypergonadotrophic hypogonadism.²

Why does this designation matter for rare disease drug development broadly?

Ultra-rare and rare disease programs like GLM101's face development challenges that go beyond any single company's data package. Speaking generally about ultra-rare disease drug development — not about Glycomine or GLM101 specifically — Joe Katakowski, director of Research at the RTW Foundation, has described the space as uniquely resource-constrained: "[Rare] disease foundations have challenges [to] getting access to the same resources and expertise that drug development companies would have; that's mainly due [to] their small patient population sizes," he said in an interview with BioPharm International.³ Smaller developers, he noted, "are sort of expected to develop [drugs] in the same regulatory structure and environment as other biotech and pharma developers" despite far more limited resources.³ A Breakthrough Therapy designation, which grants more frequent FDA engagement, is one of the few mechanisms available to help close that gap for programs like GLM101's.

What's next for GLM101?

With topline randomized Phase 2b POLAR data expected in Q4 2026, the Breakthrough Therapy designation positions Glycomine for more frequent FDA engagement as it interprets those results and plans next steps toward a potential filing.¹ "We are grateful to the patients, families, caregivers, and investigators who have made this work possible and look forward to sharing the results later this year," Axon said.¹

References

1. Glycomine, Inc. FDA Grants Breakthrough Therapy Designation to Glycomine's GLM101 for the Treatment of PMM2-CDG. Press release. Accessed September 23, 2026.
2. Phosphomannomutase 2-congenital disorder of glycosylation: exploring the role of N-glycosylation on the endocrine axes. Peer-reviewed review article, accessed via PMC. 2025.
3. Haigney S. INTERPHEX 2025: The Challenge of Developing Ultra-Rare Disease Treatments. BioPharm International. Published April 11, 2025. Accessed September 23, 2026.